PTO/SB/25 (10-00)

Approved for use through 10/21/2002 OMB 0661-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Page work Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER OTHER PENDING APPLICATIONS

Docket Number (Optional) PLOVIN-1 A

In re Applic: 'Irin of, Wolfgang HEIL et al.

Application No. 09/654,227

Filed: August 31, 2000

For PHATMACEUTICAL COMPOSITION FOR USE AS A CONTRACEPTIVE

The owner*. <u>Scheding Aktiengesellschaft</u> of <u>100</u> percent interest by virtue of an assignment document recorded on January 26, 2001 (Reel 011460/Frame 0030), in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration c: tr of the full statutory term defined in 35 U S C 154 to 156 and 173 as shortened by any terminal disclaimer expiration 6: if of the full statutory term defined in 35 0.5 () for to 156 and 173 as shortened by any terminal discounter filled prior to the grant of any patent granted on pending Application Number 10/359,062, filed on February 6, 2003; Application Number 10/359,062, filed on February 6, 2003; Application Number 10/359,062, filed on February 6, 2003; The owner hereby agrees that any patent so granted on the Instant application shall be enforceable only for and during such period. that it and the patent granted on the second application are commonly owned. This agreement runs with any batent granted on the instant application and is binding upon the grantee, its successors or assigns.

In wasking the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent cranted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction. Is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cane "it d by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory terin as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate

1. 🔲	12 submissions on behalf of an organization (e.g., corporation, partnership, university, government agency,
_	e c), the undersigned is empowered to act on behalf of the organization.

I he reby declare that all statements made herein of my own knowledge are true and that all statements made on Information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statemants and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent Issued there x

2. 🛛 The undersigned is an attorney of record.

March 26, 2004

Date

John A. Sapp. Reg. No. 33,103 Typed or Printed Name

■Terminal fiscialmer fee under 37 CFR 1.20(d) is authorized to be charged to Deposit Account No. 13-3402.

WARNING: Information on this form may become public. Credit card information should not he included on this form. Provide credit card information and authorization on PTO-2038.

*Statemrin under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner) Form ***TO/SB/96 may be used for making this certification. See MPEP § 324.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the semination of time you are required to complete this form should be seminated to the Chief information Officer, U.S. Patent and Trademark Office. Washington, DC 20231-DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Commissioner of Patents. P.O. Ethical Section 1450. Alexandria, VA 22313-1450.